Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Using a nanoparticle-containing triple drug treatment to target TNBC cells, CSC populations & tumor vasculature.

EF 2018-19

Résumé
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer accounting for the majority of breast cancer related death. Due to the lack of targeted therapy in TNBC, chemotherapeutics such as, paclitaxel (P), are the primary treatment but enrich a subpopulation of cells with tumor initiating capacity called cancer stem cells (CSCs). verteporfin (Vp), an FDA approved drug, was shown to inhibit YAP driven oncogenic growth in solid tumors. Preliminary results show that Vp is able to inhibit paclitaxel-mediated up-regulation of key pathways implicated in the self-renewal of breast CSCs. I have also found that the addition of Combretastatin (C), a tumor growth and angiogenesis inhibitor, to P and Vp was able to decrease cell viability and cell migration more than single or double drug combination. Nanomedicine has been used in multi-drug treatments to allow for controlled drug release and reduce off-target toxicities. In this study, I will determine the potency of using the triple drug (PVC) nanoparticle encapsulated treatment in a clinically relevant in vivo model. I will also investigate the mechanism by which the triple drug overlap in combatting tumor progression and CSC regulation. Thus, my research will evaluate the possibly of using combination therapy in TNBC treatment to simultaneously target TNBC bulk, CSCs and vasculature, for potential future clinical application.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406448
Name
El-Sahli Sara
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using a nanoparticle-containing triple drug treatment to target TNBC cells, CSC populations & tumor vasculature.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Breast Cancer; Cancer Stem Cells; Chemotherapy; Inhibition; Multi-Drug Treatment; Nanoparticles; Triple Negative Breast Cancer; Tumor Growth; Yap Signalling
Abstract
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer accounting for the majority of breast cancer related death. Due to the lack of targeted therapy in TNBC, chemotherapeutics such as, paclitaxel (P), are the primary treatment but enrich a subpopulation of cells with tumor initiating capacity called cancer stem cells (CSCs). verteporfin (Vp), an FDA approved drug, was shown to inhibit YAP driven oncogenic growth in solid tumors. Preliminary results show that Vp is able to inhibit paclitaxel-mediated up-regulation of key pathways implicated in the self-renewal of breast CSCs. I have also found that the addition of Combretastatin (C), a tumor growth and angiogenesis inhibitor, to P and Vp was able to decrease cell viability and cell migration more than single or double drug combination. Nanomedicine has been used in multi-drug treatments to allow for controlled drug release and reduce off-target toxicities. In this study, I will determine the potency of using the triple drug (PVC) nanoparticle encapsulated treatment in a clinically relevant in vivo model. I will also investigate the mechanism by which the triple drug overlap in combatting tumor progression and CSC regulation. Thus, my research will evaluate the possibly of using combination therapy in TNBC treatment to simultaneously target TNBC bulk, CSCs and vasculature, for potential future clinical application.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
El-Sahli, Sara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~